

CDC Drops Quarantine, Distancing Recommendations, as 1.3 Million COVID Vaccine Injuries Reported to VAERS

By [Megan Redshaw](#)

Global Research, August 14, 2022

[Children's Health Defense](#) 12 August 2022

Region: [USA](#)

Theme: [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

To receive Global Research’s Daily Newsletter (selected articles), [click here](#).

Follow us on [Instagram](#) and [Twitter](#) and subscribe to our [Telegram Channel](#). Feel free to repost and share widely Global Research articles.

The Centers for Disease Control and Prevention (CDC) today released new data showing a total of [1,379,438 reports of adverse events](#) following [COVID-19](#) vaccines were submitted between Dec. 14, 2020, and Aug. 5, 2022, to the Vaccine Adverse Event Reporting System (VAERS). That’s an increase of 7,964 adverse events over the previous week.

VAERS is the primary government-funded system for reporting adverse vaccine reactions in the U.S.

The data included a total of [30,162 reports of deaths](#) — an increase of 181 over the previous week — and [251,075 serious injuries](#), including deaths, during the same time period — up 1,959 compared with the previous week.

Of the 30,162 reported deaths, [19,462 cases](#) are attributed to Pfizer’s COVID-19 vaccine, [8,038 cases](#) to Moderna, [2,613 cases](#) to Johnson & Johnson (J&J) and [no cases](#) yet reported for Novavax.

Excluding “[foreign reports](#)” to VAERS, [854,084 adverse events](#), including [13,972 deaths](#) and [87,488 serious injuries](#), were reported in the U.S. between Dec. 14, 2020, and Aug. 5, 2022.

[Foreign reports](#) are reports foreign subsidiaries send to U.S. vaccine manufacturers. Under U.S. Food and Drug Administration (FDA) regulations, if a manufacturer is notified of a foreign case report that describes an event that is both serious and does not appear on the product’s labeling, the manufacturer is required to submit the report to VAERS.

Of the 13,972 U.S. [deaths reported](#) as of Aug. 5, 7% occurred within 24 hours of vaccination, 15% occurred within 48 hours of vaccination and 54% occurred in people who experienced an [onset of symptoms](#) within 48 hours of being vaccinated.

In the U.S., 604 million COVID-19 vaccine doses had been administered as of Aug. 3, [including](#) 357 million doses of Pfizer, 228 million doses of Moderna and 19 million doses of Johnson & Johnson (J&J).



National Vaccine
Information Center
Your Health. Your Family. Your Choice.

Search Results

From the 8/5/2022 release of VAERS data:

Found 1,379,438 cases where Vaccine is COVID19

[Government Disclaimer on use of this data](#)

Table		
↓ Event Outcome	↑ ↓ Count	Percent
Death	30,162	2.19%
Permanent Disability	56,477	4.09%
Office Visit	202,530	14.68%
Emergency Room	120	0.01%
Emergency Doctor/Room	133,570	9.68%
Hospitalized	172,155	12.48%
Hospitalized, Prolonged	435	0.03%
Recovered	354,716	25.71%
Birth Defect	1,141	0.08%
Life Threatening	33,475	2.43%
Not Serious	647,629	46.95%
TOTAL	† 1,632,410	† 118.34%
† Because some cases have multiple vaccinations and symptoms, a single case can account for multiple entries in this table. This is why the Total Count is greater than 1,379,438 (the number of cases found), and the Total Percent is greater than 100.		

Every Friday, [VAERS](#) publishes vaccine injury reports received as of a specified date. Reports submitted to VAERS require further investigation before a causal relationship can be confirmed.

Historically, VAERS has been shown to report only [1% of actual vaccine adverse events](#).

VAERS data from Dec. 14, 2020, to Aug. 5, 2022, for 6-month-olds to 5-year-olds show:

- [2,975 adverse events](#), including [140 cases rated as serious](#) and [5 reported deaths](#).
- [4 reports](#) of myocarditis and pericarditis (heart inflammation).
The CDC uses a [narrowed case definition](#) of “myocarditis,” which [excludes cases](#) of cardiac arrest, [ischemic strokes](#) and deaths due to heart problems that occur before one has the chance to go to the emergency department.
- [20 reports](#) of blood clotting disorders.
- [38 reports](#) of seizures.

VAERS data from Dec. 14, 2020, to Aug. 5, 2022, for 5- to 11-year-olds show:

- [13,364 adverse events](#), including [620 rated as serious](#) and [22 reported deaths](#).
- [45 reports](#) of myocarditis and pericarditis.
- [64 reports](#) of blood clotting disorders.
- [169 reports](#) of seizures.

VAERS data from Dec. 14, 2020, to Aug. 5, 2022, for 12- to 17-year-olds show:

- [32,945 adverse events](#), including [4,189 rated as serious](#) and [118 reported deaths](#).

According to the CDC, “VAERS data [available to the public](#) include only the initial report data to VAERS. Updated data which contains data from medical records and corrections reported during follow up are used by the government for analysis. However, for numerous reasons including data consistency, these amended data are not available to the public.”

- [268 reports](#) of anaphylaxis among 12- to 17-year-olds where the reaction was life-threatening, required treatment or resulted in death — with 94% of cases attributed to [Pfizer’s vaccine](#).
- [1,304 reports](#) of myocarditis and pericarditis with [650 cases](#) attributed to Pfizer’s vaccine.
- [298 reports](#) of blood clotting disorders with [275 cases](#) attributed to Pfizer.
- [26 cases](#) of postural orthostatic tachycardia syndrome (POTS) with [all cases](#) attributed to Pfizer’s vaccine.

VAERS data from Dec. 14, 2020, to Aug. 5, 2022, for all age groups combined, show:

- 20% of deaths were related to cardiac disorders.
- 55% of those who died were male, 41% were female and the remaining death reports did not include the gender of the deceased.
- The [average age](#) of death was 73.
- As of Aug. 5, [12,010 pregnant women](#) reported adverse events related to COVID-19 vaccines, including [4,801 reports of miscarriage or premature birth](#).
- Of the [16,124 cases of Bell’s Palsy](#) reported, 75% were attributed to Pfizer vaccinations, 23% to Moderna and 4% to J&J.
- [2,881 reports of Guillain-Barré syndrome](#), with 66% of cases attributed to Pfizer, 20% to Moderna and 17% to J&J.
- [9,884 reports](#) of anaphylaxis where the reaction was life-threatening, required treatment or resulted in death.
- [4,663 reports](#) of myocardial infarction.
- [42,180 reports](#) of blood-clotting disorders in the U.S. Of those, [28,921 reports](#) were attributed to Pfizer, [9,445 reports](#) to Moderna and [3,754 reports](#) to J&J.
- [23,535 cases](#) of myocarditis and pericarditis with [17,890 cases](#) attributed to Pfizer, [5,226 cases](#) to Moderna and [399 cases](#) to J&J.
- [64 cases](#) of Creutzfeldt-Jakob disease with [51 cases](#) attributed to Pfizer, [12 cases](#) to Moderna and [1 case](#) to J&J.
- [493 cases](#) of POTS with [375 cases](#) attributed to Pfizer, [109 cases](#) to Moderna and [21 cases](#) to J&J.

[Children’s Health Defense](#) (CHD) asks anyone who has experienced an adverse reaction, to any vaccine, to file a report following [these three steps](#).

New CDC COVID guidance ditches distinctions between vaccinated and unvaccinated

The CDC on Thursday issued [sweeping new recommendations](#) as part of the agency’s efforts to overhaul its [COVID-19 guidance](#).

“This guidance acknowledges that the pandemic is not over, but also helps us move to a

point where COVID-19 no longer severely disrupts our daily lives,” the CDC’s Greta Massetti said in a [press release](#).

Here are the [biggest changes](#) to the CDC’s guidance:

- Unvaccinated people now have the same guidance as vaccinated people.
- Those who are exposed to the virus are no longer required to quarantine regardless of vaccination status.
- Students may stay in class even if they’ve been exposed to COVID-19.
- Six-foot social distancing is [no longer recommended](#).
- Contact tracing and routine surveillance testing of symptomatic people are no longer recommended in most settings.

According to [The New York Times](#), the CDC has been working for months on the new guidance which builds on previous guidance issued in February that reduced isolation times for those who get COVID-19.

The agency said it is making changes to its guidance now because “vaccination and prior infections have granted many Americans some degree of protection against the virus, and treatments, vaccines and boosters are available to reduce the risk of severe illness.”

According to [The National Law Review](#):

“The CDC’s focus on individual responsibility, the removal of distinctions between vaccinated and unvaccinated, the removal of quarantine recommendations and the discussion of mask wearing as an individual responsibility are good news for employers who are considering relaxing COVID-19 workplace requirements.

“This likely will not be the last we hear from the CDC on this topic. Indeed, the CDC stated that it intends to issue more specific guidance for settings such as healthcare, congregate living, and travel.”

Pfizer vaccine efficacy in teens wanes 27 days after second dose

A [study](#) published Aug. 8 in The Lancet showed the effectiveness of the Pfizer-BioNTech COVID-19 vaccine against symptomatic infection among adolescents “rapidly declined over time,” waning from just 27 days after the second dose.

Researchers [analyzed data](#) from 503,776 COVID-19 tests of 2,948,538 adolescents — ages 12-17 — in Brazil from Sept. 2, 2021, to April 19, 2022, and 127,168 tests of 404,673 adolescents in Scotland from Aug. 6, 2021, to April 19, 2022.

The study showed vaccine efficacy began to decline 27 days after the second dose for both countries, plummeting to 5.9% (95% CI 2.2-9.4) in Brazil and dropping to 50.6% (95% CI 42.7-57.4) in Scotland at 98 days after adolescents received the second dose.

While protection against symptomatic COVID-19 dropped dramatically in both countries less than one month after the second dose, protection against severe illness — defined as hospitalization or death within 28 days — remained above 80% in Brazil from 28 days to 98 days and beyond.

The authors [sought to assess protection](#) against severe illness in Scotland but were unable

to do so because so few cases of severe COVID-19 in adolescents in Scotland were reported during the time of the study.

The authors concluded that “two doses are insufficient to sustain protection against symptomatic disease” in adolescents and recommended more research be done on the need for [booster doses](#).

‘Stunning’ link between Pfizer vaccine and myocarditis in teens, study shows

A [preprint study](#) conducted during Thailand’s national COVID-19 vaccination campaign showed what one physician described as a “[stunning](#)” association between myocarditis and the Pfizer-BioNTech vaccine.

The study analyzed 301 participants ages 13-18 who were healthy and without abnormal symptoms after receiving their first vaccine dose. Participants with a history of cardiomyopathy, tuberculous pericarditis or constrictive pericarditis and severe allergic reaction to the COVID-19 vaccine were excluded from the study.

Researchers found that 18% of the 301 teens analyzed had an abnormal electrocardiogram, or EKG after receiving their second dose of Pfizer, 3.5% of males developed myopericarditis or [subclinical myocarditis](#), two were hospitalized and one was admitted to the ICU for heart problems.

Cardiovascular adverse events observed during the study included tachycardia (7.64%), shortness of breath (6.64%), palpitation (4.32%), chest pain (4.32%) and hypertension (3.99%).

Fifty-four adolescents had abnormal electrocardiograms after vaccination, three patients had minimal [pericardial effusion](#) with findings compatible with subacute myopericarditis and six patients experienced [mitral valve prolapse](#).

All patients were male and had abnormal electrocardiograms, particularly sinus tachycardia. [Researchers said](#) the clinical course was mild in all cases.

Military using ‘Comirnaty’ vaccine produced at facility not approved by FDA

In an [exclusive interview](#) with The Defender, a U.S. Coast Guard (USCG) service member alleged the U.S. Department of Defense (DOD) is administering COVID-19 vaccines from vials of [Pfizer’s Comirnaty-labeled vaccines](#) that are not produced in a facility approved by the FDA.

Lt. Chad R. Coppin, in a July 30 [declaration](#) submitted to Sen. Ron Johnson (R-Wis.) under penalty of perjury, detailed his personal investigation into the availability and origin of Comirnaty-labeled COVID-19 vaccine vials at U.S. military facilities.

Coppin relayed his concerns in an interview with [The Defender](#), as did Holly Freinle, the wife of a U.S. military service member stationed at Fort Detrick, Maryland, who corroborated Coppin’s claims that Comirnaty-labeled vaccine vials are appearing at military service facilities.

Until now, the DOD has claimed the Pfizer-BioNTech COVID-19 vaccine, administered under [Emergency Use Authorization](#), is “[interchangeable](#)” with the fully licensed Pfizer Comirnaty

vaccine — which until recently, was said to be unavailable at military facilities.

In his [July 30 declaration](#), Coppin, who has served with the USCG since March 2002, reported that after a long period of unavailability, the “Comirnaty” vaccine began to appear at U.S. military facilities in June.

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram and Twitter and subscribe to our Telegram Channel. Feel free to repost and share widely Global Research articles.

Megan Redshaw is a staff attorney for Children's Health Defense and a reporter for The Defender.

Featured image is from CHD

The original source of this article is [Children's Health Defense](#)
Copyright © [Megan Redshaw](#), [Children's Health Defense](#), 2022

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Megan Redshaw](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca
www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca